@article{article_1427896, title={Evaluation of the efficacy of pretreatment chest CT markers in predicting response to neoadjuvant chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC)}, journal={Journal of Cukurova Anesthesia and Surgical Sciences}, volume={7}, pages={32–41}, year={2024}, DOI={10.36516/jocass.1427896}, author={Akkaya, Hüseyin and Dılek, Okan and Revanlı Saygılı, Rukiye Aysu and Gulmez, Ahmet and Coşkun, Hatice and Taş, Zeynel Abidin and Gülek, Bozkurt}, keywords={neoadjuvant chemoradiotherapy, non-small cell lung cancer, chest CT, prognosis, pathologic response}, abstract={Aim: To investigate baseline enhanced chest CT findings that may predict progression or response to neoadjuvant chemoradiotherapy. Materials and methods: Multiple parameters to be obtained from baseline enhanced chest CT scans of 140 patients with NSCLC who had baseline enhanced chest CT scans before neoadjuvant chemoradiotherapy were noted. In addition to CT features of tumour tissues, age, gender, tumour cell types, lymph node TNM stages, distant metastases on baseline enhanced chest CT, bronchial and vascular invasion were also evaluated. Chest CT findings and changes in tumour tissue at 3 and 6 months during neoadjuvant treatment were noted. Patients were operated after the end of neoadjuvant treatment. It was investigated which parameters could predict response to neoadjuvant treatment and which findings could predict progression. Results: Progression and mortality rates were found to be low in patients with remission (p <0.001). None of the parameters on baseline chest CT before neoadjuvant treatment predicted response to neoadjuvant treatment. According to the results of the analysis, patients with lymph node station had a 3.69 -fold efect [odds ratio (OR)=3.693, [95% confdence interval (CI)= 1.875–7.274, p=0.041] effect on progression (p <0.001). Conclusion: It has been observed that any of the parameters that can be obtained from baseline chest CT examination before neoadjuvant treatment are not successful in predicting neoadjuvant treatment response. Lymph node is the only baseline chest CT finding that can predict progression.}, number={1}, publisher={Merthan TUNAY}